Akebia Therapeutics Inc. (NASDAQ: AKBA) established initial surge of 1.30% at $1.56, before settling in for the price of $1.54 at the close. Taking a more long-term approach, AKBA posted a 52-week range of $0.53-$2.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 5.16%. Meanwhile, its Annual Earning per share during the time was 35.46%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 0.32%. This publicly-traded company’s shares outstanding now amounts to $194.58 million, simultaneously with a float of $184.15 million. The organization now has a market capitalization sitting at $326.62 million. At the time of writing, stock’s 50-day Moving Average stood at $1.6312, while the 200-day Moving Average is $1.2983.
Akebia Therapeutics Inc. (AKBA) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Akebia Therapeutics Inc. industry. Akebia Therapeutics Inc.’s current insider ownership accounts for 12.05%, in contrast to 18.43% institutional ownership. According to the most recent insider trade that took place on Feb 29 ’24, this organization’s CEO and President sold 46,570 shares at the rate of 1.58, making the entire transaction reach 73,581 in total value, affecting insider ownership by 2,044,580. Preceding that transaction, on Feb 29 ’24, Company’s SVP, Chief Operating Officer sold 8,661 for 1.58, making the whole transaction’s value amount to 13,684. This particular insider is now the holder of 706,932 in total.
Akebia Therapeutics Inc. (AKBA) Earnings and Revenue Records
Going through the last 3-months fiscal report unveiled on the 12/30/2023, it has been observed that the corporation posted $0 earnings per share (EPS) during the time that was better the consensus figure (set at -$0.04) by $0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
Akebia Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 0.32% and is forecasted to reach -0.27 in the upcoming year.
Akebia Therapeutics Inc. (NASDAQ: AKBA) Trading Performance Indicators
Let’s observe the current performance indicators for Akebia Therapeutics Inc. (AKBA). It’s Quick Ratio in the last reported quarter now stands at 1.03. The Stock has managed to achieve an average true range (ATR) of 0.18. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.68.
In the same vein, AKBA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.28, a figure that is expected to reach -0.07 in the next quarter, and analysts are predicting that it will be -0.27 at the market close of one year from today.
Technical Analysis of Akebia Therapeutics Inc. (AKBA)
Now, what If we examine the latest scores posted by [Akebia Therapeutics Inc., AKBA]. During the last 5-days, its volume was better the volume of 4.48 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 11.64% While, its Average True Range was 0.1852.
Raw Stochastic average of Akebia Therapeutics Inc. (AKBA) in the period of the previous 100 days is set at 39.81%, which indicates a major rise in contrast to 13.21% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 124.05% that was higher than 84.29% volatility it exhibited in the past 100-days period.
